Know Cancer

or
forgot password

Pharmacogenetics of Gemtuzumab Ozogamicin (GO) Therapy in Acute Myeloid Leukemia


N/A
N/A
29 Years
Open (Enrolling)
Both
Leukemia

Thank you

Trial Information

Pharmacogenetics of Gemtuzumab Ozogamicin (GO) Therapy in Acute Myeloid Leukemia


OBJECTIVES:

- To genotype the genomic DNA from acute myeloid leukemia (AML) patients treated on
COG-AAML0531 clinical trial for CD33 (and PgP and SOC3) single nucleotide polymorphisms
(SNPs).

OUTLINE: Archived DNA samples are analyzed for single nucleotide polymorphisms in CD33, PgP,
and SOC3 genes by Sequenome platform. Results are then compared with patients clinical
outcomes, including minimal-residual disease levels post induction I (chemotherapy and
gemtuzumab ozogamicin), complete remission rates, refractory disease with various levels of
bone marrow blasts, development of CNS/persistent disease, event-free survival, overall
survival, and toxicity.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Diagnosed with acute myeloid leukemia

- DNA samples from patients treated on COG-AAML0531

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Genetic changes in CD33 impact outcome of gemtuzumab ozogamicin-based therapy

Safety Issue:

No

Principal Investigator

Jatinder Lamba, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Masonic Cancer Center, University of Minnesota

Authority:

United States: Federal Government

Study ID:

CDR0000706823

NCT ID:

NCT01407757

Start Date:

July 2011

Completion Date:

Related Keywords:

  • Leukemia
  • adult acute myeloid leukemia with 11q23 (MLL) abnormalities
  • adult acute myeloid leukemia with del(5q)
  • adult acute myeloid leukemia with inv(16)(p13;q22)
  • adult acute myeloid leukemia with t(16;16)(p13;q22)
  • adult acute myeloid leukemia with t(8;21)(q22;q22)
  • untreated adult acute myeloid leukemia
  • untreated childhood acute myeloid leukemia and other myeloid malignancies
  • adult acute basophilic leukemia
  • childhood acute basophilic leukemia
  • adult acute eosinophilic leukemia
  • childhood acute eosinophilic leukemia
  • adult acute myeloblastic leukemia without maturation (M1)
  • childhood acute myeloblastic leukemia without maturation (M1)
  • adult acute minimally differentiated myeloid leukemia (M0)
  • childhood acute minimally differentiated myeloid leukemia (M0)
  • adult acute myeloblastic leukemia with maturation (M2)
  • childhood acute myeloblastic leukemia with maturation (M2)
  • adult acute myelomonocytic leukemia (M4)
  • childhood acute myelomonocytic leukemia (M4)
  • adult acute monoblastic leukemia (M5a)
  • adult acute monocytic leukemia (M5b)
  • childhood acute monoblastic leukemia (M5a)
  • childhood acute monocytic leukemia (M5b)
  • adult erythroleukemia (M6a)
  • adult pure erythroid leukemia (M6b)
  • childhood acute erythroleukemia (M6)
  • adult acute megakaryoblastic leukemia (M7)
  • childhood acute megakaryocytic leukemia (M7)
  • recurrent adult acute myeloid leukemia
  • recurrent childhood acute myeloid leukemia
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid

Name

Location